Tesamorelin and Glucose Homeostasis: Insulin Sensitivity, HbA1c and Glycaemic Safety Signals Across the Trials

RESEARCH · TESAMORELIN · GLUCOSE AND INSULIN SENSITIVITY

Tesamorelin and Glucose Homeostasis: Insulin Sensitivity, HbA1c and Glycaemic Safety Signals Across the Trials

PurixLab’s Tesamorelin 5mg is a research vial of the stabilised GHRH(1-44) analogue. Our earlier articles cover a research overview, visceral fat and liver fat, pharmacokinetics and GH pulsatility and muscle, lipids and inflammatory markers. This article follows a single thread through the published trials: glucose. Growth hormone raises blood glucose and lowers insulin sensitivity, so any compound that increases GH secretion has to answer the same question. These are published findings from clinical research under medical supervision; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

Why glucose is the central safety question

The comparison point is recombinant human growth hormone (rhGH). In a 12-week factorial trial in people with HIV, abdominal obesity and insulin resistance, rhGH reduced visceral fat by 22.7% but also lowered insulin sensitivity, and fasting glucose and the glucose area under the curve on an oral glucose tolerance test rose relative to control. Adding rosiglitazone reversed the insulin sensitivity effect without changing the fat loss [1]. Even a low, physiological rhGH regimen titrated to the upper quartile of normal IGF-1, given for 18 months, reduced visceral fat but raised 2-hour glucose on tolerance testing, with a treatment effect of 22 mg/dL [2].

The rationale for GHRH analogues is that stimulating the pituitary keeps GH release pulsatile and under feedback control. An early 12-week trial of native GHRH in 31 men with HIV lipodystrophy reported that IGF-1 rose (104 vs 6 ng/mL with placebo), trunk fat fell and lean mass increased, while glucose, insulin and lipids did not change significantly [3].

Clamp data in healthy men

The most direct measure of insulin sensitivity is the euglycaemic hyperinsulinaemic clamp. In 13 healthy men treated for 2 weeks, tesamorelin increased mean overnight GH, GH pulse area and basal GH secretion, and IGF-I rose by 181 micrograms per litre. Neither fasting glucose (P = 0.93) nor insulin-stimulated glucose uptake (P = 0.61) changed significantly [4]. The study was small and short, but it is one of the few to use a clamp.

The HIV phase 2 and phase 3 programme

Glucose was tracked as a safety measure throughout the registration trials:

  • Phase 2 study. In 61 patients over 12 weeks, IGF-I increased by 48% and 65% in the two active arms, trunk fat fell in the higher arm, and treatment was well tolerated without changes in glucose [5].
  • First phase 3 trial. In 412 patients randomised for 26 weeks, visceral fat fell by 15.2% versus a 5.0% increase with placebo, and no significant differences were observed in glycaemic measures, including glucose and insulin levels [6]. In the extension phase, changes in glucose parameters over 52 weeks were not clinically significant and were similar to those at 26 weeks [7].
  • Second phase 3 trial. In 404 patients, IGF-I increased but no change in glucose parameters was observed, and visceral fat fell by about 18% in those continuing for 12 months [8].
  • Pooled analysis. Across 806 randomised patients, the authors reported no clinically meaningful differences between groups in glucose parameters at weeks 26 and 52 [9].

Responders and non-responders: a revealing split

A post hoc analysis of the phase 3 data separated participants by how much visceral fat they lost. Those with at least an 8% reduction were defined as responders. At 52 weeks, fasting glucose changed by -1 ± 14 mg/dL in responders but by 8 ± 17 mg/dL in non-responders, and haemoglobin A1c changed by 0.0 ± 0.3% versus 0.2 ± 0.5%. Changes in glucose homeostasis were significantly associated with the percentage change in visceral fat, and adiponectin improved in responders [10].

One reading is that a direct GH effect tends to raise glucose while visceral fat loss offsets it, so the net result depends on how much fat is lost. The analysis was post hoc and shows an association, not a cause, but it explains why averaged results can look flat.

A transient early signal

A 6-month trial in 50 people with HIV and abdominal fat accumulation measured glucose more often. Fasting glucose rose in the tesamorelin group at 2 weeks, with a treatment effect of 7 mg/dL (P = .03), but changes in fasting glucose over 6 months were not significant overall (P = .72), and neither were 2-hour glucose values (P = .53) [11]. Trials that measure only at baseline and at the end could miss short-lived changes of this kind.

Beyond HIV: obesity and type 2 diabetes

  • Abdominal obesity with reduced GH. In a 12-month randomised trial of 60 abdominally obese people with reduced GH secretion and no HIV, tesamorelin reduced visceral fat (treatment effect -35 cm2), triglycerides, C-reactive protein and carotid intima-media thickness, and no changes in fasting glucose, 2-hour glucose or glycated haemoglobin were seen [12].
  • Type 2 diabetes. A 12-week placebo-controlled trial in 53 people with type 2 diabetes was designed specifically to test whether tesamorelin alters insulin sensitivity or diabetes control. There were no significant differences in relative insulin response, and fasting glucose, HbA1c and overall diabetes control did not differ at week 12. Changes in diabetes medication were similar across groups, and no participant discontinued because of loss of diabetes control [13].

Liver-fat trials and newer regimens

In a 12-month trial of people with HIV and fatty liver, glucose was the primary safety endpoint. Changes in fasting glucose and glycated haemoglobin were not different between groups at 12 months [14]. A secondary analysis of 38 participants on integrase inhibitor-based regimens, a drug class introduced after the phase 3 trials, found a similar frequency of adverse events, including hyperglycaemia, between groups [15]. Liver biopsy data from the same trial showed that hepatic IGF1 mRNA was inversely related to glucose parameters, and GHRH treatment increased circulating IGFBP-1 and IGFBP-3 while lowering IGFBP-2 and IGFBP-6 [16]. A 2026 meta-analysis of five randomised trials concluded that tesamorelin improved body composition and hepatic fat without perturbation of glucose [17].

Reading this evidence critically

  • Mostly fasting measures. Only the small healthy-volunteer study used a clamp [4]; most trials relied on fasting glucose, insulin, HbA1c or oral glucose tolerance.
  • Limited duration. The longest randomised data cover about a year [9,14], which is short for a glycaemic outcome.
  • Averages hide subgroups. The responder analysis shows that a neutral average can contain a group with rising glucose [10].

What remains open

  • Whether glucose remains stable beyond a year of exposure.
  • Whether the early, transient rise in fasting glucose reflects a consistent pattern.
  • Which baseline features predict that visceral fat will not respond, and therefore that glucose may drift upward.

Tesamorelin 5mg at PurixLab

Tesamorelin 5mg: a labelled lyophilized research vial with 5mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tesamorelin-5mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tesamorelin 5mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Glesby MJ, Albu J, Chiu YL, et al. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. PLoS One. 2013;8(4):e61160. PubMed 23593417 · PMC3625151 · doi:10.1371/journal.pone.0061160
  2. Lo J, You SM, Canavan B, et al. Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA. 2008;300(5):509-19. PubMed 18677023 · PMC2532757 · doi:10.1001/jama.300.5.509
  3. Koutkia P, Canavan B, Breu J, et al. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA. 2004;292(2):210-8. PubMed 15249570 · doi:10.1001/jama.292.2.210
  4. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-8. PubMed 20943777 · PMC3038486 · doi:10.1210/jc.2010-1587
  5. Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-87. PubMed 16052083 · doi:10.1097/01.aids.0000180099.35146.30
  6. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PubMed 18057338 · doi:10.1056/NEJMoa072375
  7. Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008;22(14):1719-28. PubMed 18690162 · doi:10.1097/QAD.0b013e32830a5058
  8. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22. PubMed 20101189 · doi:10.1097/QAI.0b013e3181cbdaff
  9. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291-304. PubMed 20554713 · doi:10.1210/jc.2010-0490
  10. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-51. PubMed 22495074 · PMC3348954 · doi:10.1093/cid/cis251
  11. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-9. PubMed 25038357 · PMC4363137 · doi:10.1001/jama.2014.8334
  12. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97(12):4769-79. PubMed 23015655 · PMC3513535 · doi:10.1210/jc.2012-2794
  13. Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017;12(6):e0179538. PubMed 28617838 · PMC5472315 · doi:10.1371/journal.pone.0179538
  14. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830. PubMed 31611038 · PMC6981288 · doi:10.1016/S2352-3018(19)30338-8
  15. Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764. PubMed 38905488 · PMC11365754 · doi:10.1097/QAD.0000000000003965
  16. Stanley TL, Fourman LT, Zheng I, et al. Relationship of IGF-1 and IGF-Binding Proteins to Disease Severity and Glycemia in Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2021;106(2):e520-e533. PubMed 33125080 · PMC7823253 · doi:10.1210/clinem/dgaa792
  17. Badran AS, Helal A, Shata KS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. PubMed 41545261 · doi:10.1016/j.orcp.2026.01.002

Leave a Comment

Your email address will not be published. Required fields are marked *